Overexpression of Gremlin promotes non-small cell lung cancer progression

Tumor Biology

Volumn 37, Issue 2, 2016, Pages 2597-2602

  Yin, Yunhong ^a   Yang, Yie ^b   Yang, Liyun ^a   Yang, Yan ^a   Li, Chunyu ^a   Liu, Xiao ^a   Qu, Yiqing ^a  

^a SHANDONG UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SHANDONG FIRST MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Chemoresistance; EGFR TKI; Gremlin; Lung cancer; NSCLC; PC 9 GR cells; Proliferation

Indexed keywords

GEFITINIB; GREMLIN; MEMBRANE PROTEIN; OSTEOGENIC PROTEIN 1; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; BMP7 PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; MESSENGER RNA; PROTEIN KINASE INHIBITOR; SIGNAL PEPTIDE;

APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER STAGING; CELL DENSITY; CELL PROLIFERATION; CELL VIABILITY; CHEMOLUMINESCENCE; CONTROLLED STUDY; GENE AMPLIFICATION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG CARCINOGENESIS; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; DISEASE COURSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; PATHOLOGY; TUMOR CELL LINE;

APOPTOSIS; BONE MORPHOGENETIC PROTEIN 7; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LUNG NEOPLASMS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, MESSENGER; RNA, SMALL INTERFERING;

EID: 84944707438     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-4093-8     Document Type: Article

References (17)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–29.
2. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10).
3. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26(21):3543–51.
4. Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12(8):735–42.
5. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–57.
6. Ciuleanu T, Stelmakh L, Cicenas S, Miliauskas S, Grigorescu AC, Hillenbach C, et al. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol. 2012;13:300–8.
7. Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczésna A, Juhasz E, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2010;11:521–9.
8. Church RH, Krishnakumar A, Urbanek A, Geschwindner S, Meneely J, Bianchi A, et al. Gremlin1 preferentially binds to bone morphogenetic protein-2 (BMP-2) and BMP-4 over BMP-7. Biochem J. 2015;466(1):55–68.
9. Wellbrock J, Harbaum L, Stamm H, Hennigs JK, Schulz B, Klose H, et al. Intrinsic BMP antagonist gremlin-1 as a novel circulating marker in pulmonary arterial hypertension. Lung. 2015;193(4):567–70.
10. Rajski M, Saaf A, Buess M. BMP2 response pattern in human lung fibroblasts predicts outcome in lung adenocarcinomas. BMC Med Genomics. 2015;8:16.
11. Wang DJ, Zhi XY, Zhang SC, Jiang M, Liu P, Han XP, et al. The bone morphogenetic protein antagonist Gremlin is overexpressed in human malignant mesothelioma. Oncol Rep. 2012;27(1):58–64.
12. Tamminen JA, Parviainen V, Rönty M, Wohl AP, Murray L, Joenväärä S, et al. Gremlin-1 associates with fibrillin microfibrils in vivo and regulates mesothelioma cell survival through transcription factor slug. Oncogenesis. 2013;2, e66.
13. Zhang Y, Zhang Q. Bone morphogenetic protein-7 and Gremlin: new emerging therapeutic targets for diabetic nephropathy. Biochem Biophys Res Commun. 2009;383(1):1–3.
14. Sneddon JB, Zhen HH, Montgomery K, van de Rijn M, Tward AD, West R, et al. Bone morphogenetic protein antagonist gremlin 1 is widely expressed by cancer-associated stromal cells and can promote tumor cell proliferation. Proc Natl Acad Sci U S A. 2006;103:14842–7.
15. Erdmann R, Ozden C, Weidmann J, Schultze A. Targeting the Gremlin-VEGFR2 axis—a promising strategy for multiple diseases? J Pathol. 2015;236(4):403–6.
16. Worthley DL, Churchill M, Compton JT, Tailor Y, Rao M, Si Y, et al. Gremlin 1 identifies a skeletal stem cell with bone, cartilage, and reticular stromal potential. Cell. 2015;160(1–2):269–84.
17. Gustafson B, Hammarstedt A, Hedjazifar S, Hoffmann JM, Svensson PA, Grimsby J, et al. BMP4 and BMP antagonists regulate human white and beige adipogenesis. Diabetes. 2015;64(5):1670–81.